A pre-administration feasibility pharmacokinetic and meal study of hyaluronidase administered as a single dose prior to subcutaneous infusion of insulin aspart in patients with type 1 diabetes.

Trial Profile

A pre-administration feasibility pharmacokinetic and meal study of hyaluronidase administered as a single dose prior to subcutaneous infusion of insulin aspart in patients with type 1 diabetes.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2011

At a glance

  • Drugs Hyaluronidase; Insulin aspart
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2011 Status changed from active, no longer recruiting to completed.
    • 27 Oct 2011 New trial record
    • 21 Oct 2011 Results from this trial will be presented at the Diabetes Technology Meeting in October 2011, according to a Halozyme Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top